The role and efficacy of Necitumumab

The U.S. Food and Drug Administration's (FDA's approval of Necitumumab is based on the findings ofSQUIRE, an open-label In a signed, controlled phase 3 clinical trial, 1,093 patients with squamous non-small cell lung cancer were randomly assigned to the treatment group of nexituzumab (800 mg) combined with gemcitabine and cisplatin or the treatment group of gemcitabine and cisplatin alone, for a maximum of 6 cycles, or until disease progression or unacceptable toxicity.

The results showed that the median overall survival of patients in the nexituzumab group was 11.5 months, while that of patients who received gemcitabine and cisplatin alone was 9.9 months. In addition, the median progression-free survival in the nexituzumab group was 5.7 months, while that in the gemcitabine plus cisplatin group was 5.5 months. There was a significant difference between the two. There was no difference in the overall response rate between the two study groups, which was 31% in the nexituzumab group and 29% in the gemcitabine plus cisplatin group.

INSPIRE, a randomized, open-label clinical trial of 633 patients with non-squamous non-small cell lung cancer, showed no clinical benefit from the combination of nesituzumab, pemetrexed, and cisplatin. The study was terminated early due to increased rates of all-cause mortality and thromboembolic events in the nestuzumab-containing arm. Therefore, nexituzumab is not suitable for the treatment of patients with non-squamous NSCLC.

The generic drug of Nexituzumab has not yet been approved for marketing in China, and therefore it has not been included in medical insurance. The German version of the generic version of Nexituzumab available overseas800mg/50ml may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Nexituzumab on the market. For more drug information and specific prices, please consult Yaode Medical Consultant.